Contact Us
Global Headquarters
Valeant Pharmaceuticals International
Valeant Plaza
One Enterprise
Aliso Viejo, California 92656
United States of America
1.800.548.5100
1.714.545.0100
1.714.556.0131 (Fax)
US Customer Service
For product related inquiries or to request product information, please call:
US Pharmaceuticals Customer Service
1.800.556.1937
1.714.641.7289 (Fax)
Business Hours
Monday through Friday
7 a.m. – 5 p.m. PST
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.
MIGRANAL Nasal Spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina. MIGRANAL also should not be given to patients with uncontrolled hypertension, patients who have used 5-HT1 agonists, ergotamine-containing or ergot-type medications or methysergide within the last 24 hours, or patients with hemiplegic or basilar migraine. MIGRANAL Nasal Spray is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. MIGRANAL Nasal Spray should not be administered in pregnant women or nursing mothers.
Serious cardiac events, including some that have been fatal, have occurred following use of DHE 45 but are extremely rare. During clinical studies and the foreign post-marketing experience with MIGRANAL Nasal Spray, there have been no fatalities due to cardiac events.
The most commonly reported adverse events in clinical trials for MIGRANAL Nasal Spray were rhinitis, altered sense of taste, application site reactions, dizziness, nausea, and vomiting. Adverse events associated with discontinuation were rhinitis, dizziness, facial edema, cold sweats, accidental trauma, depression, elective surgery, somnolence, allergy, vomiting, hypotension, and paresthesia.
Please see accompanying complete prescribing information including BOXED warning.
Home | About Migranal | Optimize Migraine Treatment | Professional Resources
Prescribing Information | Site Map | Privacy and Legal Statement | Contact Us
